OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

1 Projects | 1 Researchers | $4,262,019 Invested

2023

GliaPharm SA

Pierre Magistretti, MD, PhD

IND-enabling studies for GliaPharm’s lead candidate to rescue hypometabolism in Alzheimer’s disease

  • Funding Amount: $4,262,019
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Mitochondria/Metabolic Function
  • Status: Active